Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $8,246 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $1,541 | $1,504 | $1,449 | $1,353 |
| Gross Profit | -$1,541 | $6,742 | -$1,449 | -$1,353 |
| % Margin | – | 81.8% | – | – |
| R&D Expenses | $106,425 | $97,127 | $85,252 | $74,081 |
| G&A Expenses | $36,231 | $42,437 | $26,055 | $22,762 |
| SG&A Expenses | $36,231 | $40,933 | $26,055 | $22,762 |
| Sales & Mktg Exp. | $0 | -$1,504 | $0 | $0 |
| Other Operating Expenses | -$921 | $0 | $7,822 | -$9,765 |
| Operating Expenses | $142,656 | $138,060 | $111,307 | $96,843 |
| Operating Income | -$142,656 | -$139,564 | -$111,307 | -$96,843 |
| % Margin | – | -1,692.5% | – | – |
| Other Income/Exp. Net | $10,882 | $7,092 | $15,069 | -$2,585 |
| Pre-Tax Income | -$131,774 | -$132,472 | -$96,238 | -$99,428 |
| Tax Expense | $138 | $188 | $123 | $107 |
| Net Income | -$131,912 | -$132,660 | -$96,361 | -$99,535 |
| % Margin | – | -1,608.8% | – | – |
| EPS | -0.73 | -0.76 | -0.61 | -0.63 |
| % Growth | 3.9% | -24.6% | 3.2% | – |
| EPS Diluted | -0.73 | -0.76 | -0.61 | -0.63 |
| Weighted Avg Shares Out | 181,611 | 174,601 | 157,499 | 157,051 |
| Weighted Avg Shares Out Dil | 181,611 | 174,601 | 157,499 | 157,051 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,455 | $15,078 | $9,891 | $9,820 |
| Interest Expense | $2,652 | $2,647 | $2,644 | $2,640 |
| Depreciation & Amortization | $1,541 | $1,504 | $1,449 | $1,353 |
| EBITDA | -$139,384 | -$128,321 | -$92,145 | -$95,435 |
| % Margin | – | -1,556.2% | – | – |